A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that stimulates urinary excretion of glucose by suppressing renal glucose reabsorption. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.
Canagliflozin has been studied across 17 research domains including 🔥 Metabolic, 🫘 Kidney, ❤️ Cardiovascular, ⏳ Longevity & Aging, 🔬 Oncology. The primary research focus is 🔥 Metabolic with 84% of studies addressing this area.
The following compounds share molecular targets with Canagliflozin, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Canagliflozin is generated deterministically from 456 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.